Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
162635-04-3
Purity
95%
Temsirolimus is a antineoplastic agent used in the treatment of renal cell carcinoma (RCC) that works by inhibiting mTOR.
Properties
Name
Temsirolimus
Smiles
CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)/[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)/[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO
Targets
Please log in to see this information
Sold for research purposes under agreement from Pfizer Inc.
Temsirolimus is an mTOR-directed antineoplastic agent widely used in oncology and translational research. As a temsirolimus small molecule, it is closely associated with studies of cell growth control, protein translation, and tumor signaling pathways regulated through mTOR. The compound is also identified by CAS 162635-04-3, which is an important reference point in supplier databases, analytical records, and compound verification workflows. According to Pfizer Medical, temsirolimus has the molecular formula C56H87NO16 and a temsirolimus molecular weight of 1030.30. These identifiers, together with temsirolimus structure and temsirolimus smiles, are commonly reviewed by researchers during compound verification, catalog comparison, and assay planning. Pfizer Temsirolimus is also well recognized in the research and clinical literature as a defined reference compound for mTOR-focused studies.
In research settings, temsirolimus is applied in oncology, kinase signaling, translational pharmacology, and pathway-focused screening. Its relevance comes from the central role of mTOR in cell proliferation, metabolism, angiogenesis, and tumor progression. Because of that, temsirolimus is often selected for experiments that examine pathway inhibition, biomarker changes, and response patterns in tumor models with PI3K/AKT/mTOR pathway involvement. In sourcing and procurement workflows, searches such as temsirolimus cost and temsirolimus price often appear alongside technical descriptors because buyers are typically evaluating both scientific fit and product traceability before selecting a supplier.
In vitro, temsirolimus has been shown to inhibit mTOR-dependent signaling and suppress growth in treated tumor cells. Pfizer labeling notes that temsirolimus binds to the intracellular protein FKBP-12, and the resulting complex inhibits mTOR activity. This leads to selective disruption of translation of key cell cycle regulatory proteins and results in G1 growth arrest in treated cells. The same source highlights downstream effects involving 4E-BP1 and S6K in the PI3 kinase/AKT pathway, making temsirolimus especially valuable in mechanistic cell-based studies that need a well-characterized mTOR inhibitor.
In vivo, Pfizer documentation reports that temsirolimus inhibited tumor cell growth in nude mouse xenograft models. This connection between defined intracellular mechanism and measurable antitumor response supports its continued use in preclinical oncology research and translational study design. Clinical labeling also reflects its established therapeutic relevance, with Pfizer identifying temsirolimus for advanced renal cell carcinoma, while EMA documentation additionally includes relapsed or refractory mantle cell lymphoma. This broader evidence base strengthens its value as a reference compound for pathway-driven cancer studies.
Biochemically, temsirolimus acts through FKBP-12-mediated inhibition of mTOR, a central regulator of cell division and protein translation. When mTOR is blocked, phosphorylation control over downstream translation factors is reduced, influencing proteins tied to cell cycle progression and hypoxia-related signaling. Physiologically, this translates into reduced proliferative signaling and suppression of tumor-supporting processes such as growth and angiogenic response. These well-defined actions explain why temsirolimus structure remains important in technical searches and why the compound is still relevant in discovery programs centered on mTOR biology.
For EBC-27516, temsirolimus offers a combination of recognized pathway relevance, clear structural identity, and strong value for modern oncology research.
SDS
CCI-779 | CCl-779 | NSC 683864 | temsirolimus | torisel
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$56
2 mg
$61
5 mg
$66
10 mg
$83
15 mg
$91
20 mg
$99
25 mg
$111
30 mg
$118
35 mg
$127
40 mg
$143
45 mg
$153
50 mg
$165
75 mg
$235
100 mg
$POA
Quantity
1
Total amount
$ 66
CCI-779 | CCl-779 | NSC 683864 | temsirolimus | torisel
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.